iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,204 · see citing works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works

RECIST 1.1—Update and clarification: From the RECIST committee

Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.081 · Cited by 1,906 · see citing works

Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,052 · see citing works

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works

Pseudoprogression and Immune-Related Response in Solid Tumors

Chiou, V. L., & Burotto, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6870 · Cited by 898 · see citing works

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal

Fife, B. T., Pauken, K. E., Eagar, T. N., Kangas, T. O., Wu, J. Q., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759 · see citing works

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Hodi, F. S., Hwu, W., Kefford, R. F., Weber, J. S., DAUD, A. I., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 735 · see citing works

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3153 · Cited by 639 · see citing works

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 608 · see citing works

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · see citing works

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522 · see citing works

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

Schwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S. J., Mandrekar, S. J., Shankar, L. K., Bogaerts, J., Chen, A. P., Dancey, J. E., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.082 · Cited by 383 · see citing works

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival

Kim, C., & Prasad, V. K. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5868 · Cited by 355 · see citing works

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, A., Parmiani, G., Hege, K. M., Sznol, M., Loibner, H., Eggermont, A. M. M., Urba, W. J., Blumenstein, B. A., Sacks, N., Keilholz, U., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211341.88835.ae · Cited by 270 · see citing works

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture

DeVita, V. T. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 164 · see citing works

Adaptation of the Immune Related Response Criteria: Irrecist

Bohnsack, O., Hoos, A., & Ludajic, K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu342.23 · Cited by 93 · see citing works

Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.

Kurra, V., Sullivan, R. J., Gainor, J. F., Hodi, F. S., Gandhi, L., Sadow, C. A., Harris, G. J., Flaherty, K. T., & Lee, S. I. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.6580 · Cited by 76 · see citing works

Tremelimumab: A Review of Development to Date in Solid Tumors

Tarhini, A. A. (2013) · Immunotherapy · doi:10.2217/imt.13.9 · Cited by 74 · see citing works

Immunotherapy as a strategy for the treatment of non-small-cell lung cancer

Holt, G. E., Podack, E. R., & Raez, L. E. (2010) · Therapy · doi:10.2217/thy.10.84 · Cited by 57 · see citing works

The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community

Liu, Y., Litière, S., de Vries, E. G. E., Sargent, D. J., Shankar, L. K., Bogaerts, J., & Seymour, L. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.10.011 · Cited by 35 · see citing works

Atezolizumab effective against advanced-stage disease

Sidaway, P. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.60 · Cited by 15 · see citing works

Top 10 Challenges in Cancer Immunotherapy

Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238 · see citing works

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · see citing works

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · see citing works

A decade of immune-checkpoint inhibitors in cancer therapy

Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608 · see citing works

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,279 · see citing works

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Vogel, A., Cervantes, A. M. R., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J., Neumann, U. P., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,047 · see citing works

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023 · see citing works

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., de Vijver, K. K. V., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 912 · see citing works

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Wang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0349-9 · Cited by 814 · see citing works

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 804 · see citing works

The Next Decade of Immune Checkpoint Therapy

Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750 · see citing works

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720 · see citing works

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B. A., Gillison, M. L., Harrington, K. J., Le, Q., Lee, N. Y., Leidner, R. S., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 719 · see citing works

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Janjigian, Y. Y., Kawazoe, A., Yanez, P. E., Li, N., Lonardi, S., Kolesnik, O., Barajas, O., Bai, Y., Shen, L., Tang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04161-3 · Cited by 722 · see citing works

mRECIST for HCC: Performance and novel refinements

Llovet, J. M., & Lencioni, R. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.026 · Cited by 689 · see citing works

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 645 · see citing works

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

Wang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12193 · Cited by 614 · see citing works

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598 · see citing works

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yanez, P. E., Wyrwicz, L. S., Shen, L., Ostapenko, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02033-0 · Cited by 544 · see citing works

Clinical Challenges of Immune Checkpoint Inhibitors

Miguel, M. J. D., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 542 · see citing works

Tumor Immunology and Tumor Evolution: Intertwined Histories

Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 541 · see citing works

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer

Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522 · see citing works

Novel patterns of response under immunotherapy

Borcoman, É., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P. L., & Tourneau, C. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 519 · see citing works

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 505 · see citing works

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

Herrera, F. G., Ronet, C., Ochoa-de-Olza, M., Barras, D., Crespo, I., Andreatta, M., Corria-Osorio, J., Spill, A., Benedetti, F., Genolet, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0003 · Cited by 466 · see citing works

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Kim, R. D., Chung, V. M., Alese, O. B., El‐Rayes, B. F., Li, D., Al‐Toubah, T., Schell, M. J., Zhou, J.-M., Mahipal, A., Kim, B., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0930 · Cited by 451 · see citing works

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12516 · Cited by 437 · see citing works

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413 · see citing works

Current Landscape of Immunotherapy in Breast Cancer: A Review

Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384 · see citing works

2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

(2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 389 · see citing works

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 382 · see citing works

Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases

Ianiro, G., Punčochář, M., Karcher, N., Porcari, S., Armanini, F., Asnicar, F., Beghini, F., Blanco-Míguez, A., Cumbo, F., Manghi, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01964-3 · Cited by 366 · see citing works

Immunotherapy in breast cancer: an overview of current strategies and perspectives

Debien, V., Caluwé, A. D., Wang, X., Piccart, M. J., Tuohy, V. K., Romano, E., & Buisseret, L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00508-3 · Cited by 387 · see citing works

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Hodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1644 · Cited by 366 · see citing works

Hyperprogressive disease: recognizing a novel pattern to improve patient management

Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 360 · see citing works

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357 · see citing works

Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges

Gandalovičová, A., Rösel, D., Fernandes, M., Veselý, P., Heneberg, P., Čermák, V., Petruzelka, L. B., Kumar, S., Sanz‐Moreno, V., & Brábek, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.008 · Cited by 350 · see citing works

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Tazdait, M., Mezquita, L., Lahmar, J., Ferrara, R., Bidault, F., Ammari, S., Balleyguier, C., Planchard, D., Gazzah, A., Soria, J., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.017 · Cited by 349 · see citing works

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Korean Liver Cancer Association (KLCA), & National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 350 · see citing works

Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment

Taı̈eb, J., Svrcek, M., Cohen, R., Basile, D., Tougeron, D., & Phelip, J. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.020 · Cited by 342 · see citing works

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J. H., Perez‐Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 301 · see citing works

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) · New England Journal of Medicine · doi:10.1056/nejmc1808251 · Cited by 277 · see citing works

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Delanoy, N., Michot, J., Comont, T., Kramkimel, N., Lazarovici, J., Dupont, R., Champiat, S., Chahine, C., Robert, C., Herbaux, C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30175-3 · Cited by 296 · see citing works

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D., Ferris, R. L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000398 · Cited by 301 · see citing works

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations

Zerdes, I., Matikas, A., Bergh, J. C. S., Rassidakis, G. Z., & Foukakis, T. (2018) · Oncogene · doi:10.1038/s41388-018-0303-3 · Cited by 295 · see citing works

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 292 · see citing works

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Kemp, R., & Prasad, V. K. (2017) · BMC Medicine · doi:10.1186/s12916-017-0902-9 · Cited by 289 · see citing works

Immunotherapy of Melanoma: Facts and Hopes

Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 279 · see citing works

Upfront FOLFOXIRI plus Bevacizumab with or without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (AtezoTRIBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial

Antoniotti, C., Rossini, D., Pietrantonio, F., Catteau, A., Salvatore, L., Lonardi, S., Boquet, I., Tamberi, S., Marmorino, F., Moretto, R., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00274-1 · Cited by 280 · see citing works

TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

Han, J., Duan, J., Bai, H., Wang, Y., Wan, R., Wang, X., Chen, S., Tian, Y., Wang, D., Fei, K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0398 · Cited by 260 · see citing works

Patterns of Response and Progression to Immunotherapy

Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 262 · see citing works

FDG PET/CT for assessing tumour response to immunotherapy

Aide, N., Hicks, R. J., Tourneau, C. L., Lheureux, S., Fanti, S., & Lopci, E. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 263 · see citing works

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262 · see citing works

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology

Bartolomucci, A., de Nóbrega, M., Ferrier, S. T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 287 · see citing works

Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients

Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255 · see citing works

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Rini, B. I., Battle, D. J., Figlin, R. A., George, D. J., Hammers, H. J., Hutson, T., Jonasch, E. W., Joseph, R. W., McDermott, D. F., Motzer, R. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0813-8 · Cited by 254 · see citing works

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Boyer, M. J., Şendur, M. A. N., Rodríguez‐Abreu, D., Park, K., Lee, D. H., Çiçin, İ., Yumuk, P. F., Orlandi, F., Leal, T. A. B., Molinier, O., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03579 · Cited by 253 · see citing works

Progress and challenges of immunotherapy in triple-negative breast cancer

Zhu, Y., Zhu, X., Tang, C., Guan, X., & Zhang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188593 · Cited by 237 · see citing works

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240 · see citing works

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Chen, L.-T., Martinelli, E., Cheng, A., Pentheroudakis, G. E., Qin, S., Bhattacharyya, G. S., Ikeda, M., Lim, H. Y., Ho, G. F., Choo, S. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.001 · Cited by 238 · see citing works

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 233 · see citing works

2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

(2019) · Korean Journal of Radiology · doi:10.3348/kjr.2019.0140 · Cited by 229 · see citing works

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Moik, F., Chan, W.-S. E., Wiedemann, S., Höeller, C., Tuchmann, F., Aretin, M., Fuereder, T., Zöchbauer‐Müller, S., Preusser, M., Pabinger, I., et al. (2020) · Blood · doi:10.1182/blood.2020007878 · Cited by 235 · see citing works

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update

Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253 · see citing works

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

Zhang, S., Mao, Y., Zhang, Z.-Y., Li, Z., Kong, C., Chen, H., Cai, P., Han, B., Ye, T., & Wang, L. (2021) · Theranostics · doi:10.7150/thno.54476 · Cited by 231 · see citing works

Overcoming Immune Evasion in Melanoma

Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 230 · see citing works

Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer

Elsholtz, F. H. J., Asbach, P., Haas, M., Becker, M., Beets‐Tan, R. G. H., Thoeny, H. C., Padhani, A. R., & Hamm, B. (2021) · European Radiology · doi:10.1007/s00330-020-07572-4 · Cited by 224 · see citing works

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., Ariyan, C. E., Bassett, R. L., Carter, B., DAUD, A. I., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30332-8 · Cited by 219 · see citing works

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Marabelle, A., Andtbacka, R. H. I., Harrington, K. J., Melero, I., Leidner, R. S., de Baère, T., Robert, C., Ascierto, P. A., Baurain, J. F., Imperiale, M. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy423 · Cited by 216 · see citing works

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer

Blomberg, O. S., Spagnuolo, L., Garner, H., Voorwerk, L., Isaeva, O. I., van Dyk, E., Bakker, N. A. M., Chalabi, M., Klaver, C., Duijst, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.014 · Cited by 217 · see citing works

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial

Mittendorf, E. A., Lu, B., Melisko, M., Hiller, J. A. P., Bondarenko, I., Brunt, A. M., Sergii, G., Petráková, K., & Peoples, G. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2867 · Cited by 214 · see citing works

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Muir, C. A., Clifton-Bligh, R. J., Long, G. V., Scolyer, R. A., Lo, S., Carlino, M. S., Tsang, V., & Menzies, A. M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab263 · Cited by 217 · see citing works

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions

Nishino, M., Hatabu, H., & Hodi, F. S. (2018) · Radiology · doi:10.1148/radiol.2018181349 · Cited by 215 · see citing works

Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer

Chen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 215 · see citing works

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 211 · see citing works

Immune Checkpoint Inhibitor Therapy in Oncology

Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 215 · see citing works

Treatment after progression in the era of immunotherapy

Billan, S., Kaidar‐Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 203 · see citing works

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

Straathof, K. C. M., Flutter, B. R., Wallace, R., Jain, N., Loka, T., Depani, S., Wright, G., Thomas, S., Cheung, G. W.-K., Gileadi, T. E., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6169 · Cited by 202 · see citing works

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Abu‐Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S. H., Otterson, G. A., Kendra, K. L., Ricciuti, B., Chiari, R., Giglio, A. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00320 · Cited by 199 · see citing works

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab

Anwar, H., Sachpekidis, C., Winkler, J. K., Kopp‐Schneider, A., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3870-6 · Cited by 198 · see citing works

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy

Jia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 194 · see citing works

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis

Abu-Sbeih, H., Ali, F. S., Wang, X., Mallepally, N., Chen, E., Altan, M., Bresalier, R. S., Charabaty, A., Dadu, R., Jazaeri, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0577-1 · Cited by 191 · see citing works

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Lee, C., Shah, A. Y., Rasco, D. W., Rao, A., Taylor, M. H., Simone, C. D., Hsieh, J. J.-D., Pinto, Á., Shaffer, D. R., Sarrió, R. G., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00241-2 · Cited by 191 · see citing works

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST

Goldfarb, L., Duchemann, B., Chouahnia, K., Zelek, L. H., & Soussan, M. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0473-1 · Cited by 187 · see citing works

Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma

Cai, J., Song, L., Zhang, F., Wu, S., Zhu, G., Zhang, P., Chen, S., Du, J.-X., Wang, B., Cai, Y., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12607 · Cited by 193 · see citing works

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27303-7 · Cited by 175 · see citing works

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

Song, Y., Zhang, B., Xin, D., Kou, X., Tan, Z., Zhang, S., Sun, M., Zhou, J., Fan, M., Zhang, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02179-2 · Cited by 178 · see citing works

Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis

Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M. (2020) · Radiology · doi:10.1148/radiol.2020200443 · Cited by 162 · see citing works

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Yamauchi, T., Hoki, T., Oba, T., Jain, V., Chen, H., Attwood, K. M., Battaglia, S., George, S., Chatta, G. S., Puzanov, I. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21619-0 · Cited by 168 · see citing works

18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma

Ito, K., Teng, R. S. Y., Schöder, H. M., Humm, J. L., Ni, A., Michaud, L., Nakajima, R., Yamashita, R., Wolchok, J. D., & Weber, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213652 · Cited by 174 · see citing works

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Bröckelmann, P. J., Goergen, H., Keller, U. B., Meißner, J., Ordemann, R., Halbsguth, T. V., Sasse, S., Sökler, M., Kerkhoff, A., Mathas, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0750 · Cited by 175 · see citing works

Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics

Dercle, L., Fronheiser, M., Lu, L., Du, S., Hayes, W., Leung, D. K., Roy, A., Wilkerson, J., Guo, P., Fojo, A. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2942 · Cited by 173 · see citing works

Practical recommendations for using ctDNA in clinical decision making

Cohen, S. A., Liu, M. C., & Aleshin, A. A. (2023) · Nature · doi:10.1038/s41586-023-06225-y · Cited by 177 · see citing works

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Anagnostou, V., Ho, C., Nicholas, G. A., Juergens, R. A., Sacher, A. G., Fung, A. S., Wheatley‐Price, P., Laurie, S. A., Levy, B. P., Brahmer, J. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02598-9 · Cited by 171 · see citing works

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Beaver, J. A., Hazarika, M., Mulkey, F. A., Mushti, S. L., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 167 · see citing works

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Chen, A. P., Sharon, E., Coyne, G. O., Moore, N., Foster, J. C., Hu, J. S., Tine, B. A. V., Conley, A. P., Read, W. L., Riedel, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303383 · Cited by 170 · see citing works

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Nowak, A. K., Lesterhuis, W. J., Kok, P., Brown, C. S. B., Hughes, B. G. M., Karikios, D. J., John, T., Kao, S. C.-H., Leslie, C., Cook, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30462-9 · Cited by 167 · see citing works

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Yang, J. C., Lee, D. H., Lee, J., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez‐Cid, J. R., Zhang, L., Yang, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02747 · Cited by 165 · see citing works

The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST

Inno, A., Russo, G. L., Salgarello, M., Corrao, G., Casolino, R., Galli, G., Modena, A., Romano, L., Pusceddu, S., Greco, F. G., et al. (2018) · Tumori Journal · doi:10.1177/0300891618766173 · Cited by 22 · see citing works

Towards evidence-based response criteria for cancer immunotherapy

Garralda, E., Laurie, S. A., Seymour, L., & de Vries, E. G. E. (2023) · Nature Communications · doi:10.1038/s41467-023-38837-3 · Cited by 29 · see citing works

iRECIST Guideline Unveiled for Immunotherapies

(2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2017-037 · Cited by 1 · see citing works

Revisiting RECIST: the case of treatment beyond progression

DAUD, A. I. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30007-x · Cited by 3 · see citing works

iRECIST: how to do it

ten Persigehl, T., Lennartz, S., & Schwartz, L. H. (2020) · Cancer Imaging · doi:10.1186/s40644-019-0281-x · Cited by 74 · see citing works